Government eases criteria for haemophilia A drug reimbursement

Korea Biomedical Review

26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug Hemlibra (emicizumab).

In January, the government expanded the reimbursement scope but added failure of immune tolerance induction treatment as the criteria for reimbursement, which made it more difficult for paediatric patients to receive Hemlibra injections.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder